Skip to main content
Paul Bleicher

Paul Bleicher
Chief Executive Officer, Optum Labs

Website | @pbleic

Paul Bleicher, MD PhD is the Chief Executive Officer of Optum Labs, an open, collaborative health care innovation center established by Mayo Clinic and Optum to attract research and development partnerships between various stakeholder groups in healthcare and accelerate the “speed of innovation” in the pursuit of improved patient health. Prior to his current role, he was Chief Medical Officer for Humedica, a next-generation clinical informatics company that provides novel business intelligence solutions to the health care and life science industry. At Humedica, which was acquired by Optum in January 2013, he was involved in all aspects of medical informatics, data analytics privacy and regulatory compliance, and product development. Prior to this, he was the founder and original CEO of Phase Forward where he helped grow the organization over an 11 year period from a concept to a publicly traded company serving in various capacities as Chief Strategy Officer and as a member of the Board of Directors until its 2010 acquisition by Oracle Corporation. Prior to founding Phase Forward, Dr. Bleicher served as Vice President of Clinical Affairs at Alpha-Beta Technology with responsibility for Phase I through III clinical development of a novel carbohydrate drug. Dr. Bleicher was previously the Director, Early Phase Services at PAREXEL International where he assisted pharmaceutical and biotechnology companies with the initial development of novel therapies.

Dr. Bleicher currently serves on the editorial boards of Applied Clinical Trials, the Drug Information Journal, and Research Practitioner. He has held various leadership positions in the Drug Information Association, including Chairman of the Steering Committee of North America for the Drug Information Association, a member of their Board of Directors and a member of the Board of the DIA Foundation. He served as a member of the Massachusetts Life Sciences Leadership Council.

In 2002, Dr. Bleicher won the Ernst and Young Entrepreneur of the Year Award in New England and was appointed to the Ernst and Young Entrepreneur’s Hall of Fame. He was in the first group of PharmaVoice’s 100 Most Inspiring Leaders in Life Sciences, and was named a Champion in Healthcare by the Boston Business Journal. He was named the 2003 recipient of the Rensselaer Alumni Association Fellows Award, and the 2011 Alumni Key Award.

Dr. Bleicher received his BS from Rensselaer Polytechnic Institute, and his MD and PhD from the University of Rochester School of Medicine and Dentistry, specializing in cellular immunology. He trained in internal medicine at the Beth Israel Hospital, and dermatology at Harvard Medical School/Massachusetts General Hospital. He did a post-doctoral fellowship at the Dana Farber Cancer Institute in molecular biology, and began his career as a physician/investigator and Assistant Professor at the Massachusetts General Hospital and Harvard Medical School.

Sessions

Salon G-F
Paul Bleicher (Optum Labs), Mark Hayward (Mayo Clinic)
Average rating: ***..
(3.00, 4 ratings)
Optum Labs was established with Mayo Clinic to enable cross-industry collaborative research and innovation to improve patient care. With other partners from across healthcare, Optum Labs will be a unique environment with the data, tools, and infrastructure necessary for leading scientists and innovators to tackle the thorniest problems in healthcare and to bridge this research into the clinic. Read more.

For exhibition and sponsorship opportunities at Strata Rx conference, contact Sharon Pierce at (203) 304-9476 or spierce@oreilly.com

For information on trade opportunities with O'Reilly conferences email mediapartners
@oreilly.com

View a complete list of Strata Rx 2013 contacts